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Abstract: Diclofenac (DCF), the most widely consumed non-steroidal anti-inflammatory drug
(NSAID) worldwide, is associated with adverse typical effects, including gastrointestinal (GI)
complications. The present study aims to better understand the topical toxicity induced by DCF
using membrane models that mimic the physiological, biophysical, and chemical environments of
GI mucosa segments. For this purpose, phospholipidic model systems that mimic the GI protective
lining and lipid models of the inner mitochondrial membrane were used together with a wide set of
techniques: derivative spectrophotometry to evaluate drug distribution at the membrane; steady-state
and time-resolved fluorescence to predict drug location at the membrane; fluorescence anisotropy,
differential scanning calorimetry (DSC), dynamic light scattering (DLS), and calcein leakage studies to
evaluate the drug-induced disturbance on membrane microviscosity and permeability; and small- and
wide-angle X-ray scattering studies (SAXS and WAXS, respectively), to evaluate the effects of DCF at
the membrane structure. Results demonstrated that DCF interacts chemically with the phospholipids
of the GI protective barrier in a pH-dependent manner and confirmed the DCF location at the lipid
headgroup region, as well as DCF’s higher distribution at mitochondrial membrane contact points
where the impairment of biophysical properties is consistent with the uncoupling effects reported for
this drug.
Keywords: diclofenac; NSAIDs; derivative spectrophotometry; steady-state and time-resolved
fluorescence; steady-state anisotropy; DLS; DSC; SAXS; WAXS; gastrointestinal topical toxicity
1. Introduction
Diclofenac (sodium 2-[2-(2,6-dichloroaniline)phenyl]acetate) (DCF) is a non-steroidal anti-
inflammatory drug (NSAID) generally used clinically, having an estimated global annual consumption
of about 940 tons, including for human and veterinary purposes [1]. Despite its vast clinical use,
DCF presents typical NSAID-related adverse effects of which gastrointestinal (GI) complications
(e.g., GI bleeding and gastric ulceration) are the most relevant [2–5]. These GI effects have been
considered to result mainly from the inhibition of cyclooxygenase (COX) enzyme, causing a decrease
of prostaglandins that exert a strong protective effect on gastric mucosa, a mechanism known as
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prostaglandin hypothesis [6]. However, it is now recognized that the induction of GI lesions involves
additional mechanisms (named the topical effect hypothesis), which are dependent on NSAIDs’
chemical structure and on their molecular ability to interact with lipids resulting in the damage of
GI mucosa and cellular mitochondria impairment [6–10] (Figure 1). Moreover, besides GI injuries,
DCF and chemical structure-related NSAIDs present, in susceptible patients, additional deleterious
effects such as hepatic, renal and cardiovascular damage that cannot be explained by the prostaglandin
hypothesis mechanism, but are instead associated with oxidative stress and topical effects such as
mitochondrial liabilities [6,11–20].
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Figure 1. (A) Schematic representation of the gastrointestinal (GI) epithelium containing extracellular 
and cellular phospholipid linings rich in phosphatidylcholine (PC) in the gel phase (Lβ′), which 
constitute a protective barrier of the GI mucosa against the attack of luminal acid (H+). The 
mitochondria outer and inner membranes (OMM and IMM) containing typical crista and contact 
points rich in bilayer prone phospholipids (e.g., PC) that produce lamellar phases (Lα) and non-
lamellar prone lipids (e.g., Cardiolipin (CL) and phosphatidylethanolamine (PE)) that produce 
inverted hexagonal phases (HII) are also represented. (B) Schematic representation of GI topical 
damage depicting the disruptive effect of non-steroidal anti-inflammatory drugs (NSAIDs) on the GI 
protective phospholipid lining. On the right are represented the possible mechanisms by which 
NSAIDs cause mitochondrial toxicity: inhibition of respiratory chain; inhibition of ATP synthase and 
translocase; blockage of cation transporters; and membrane permeabilization with the formation of 
membrane permeability transition pores (MPT). 
Figure 1. (A) Schematic representation of the gastrointestinal (GI) epithelium containing extracellular
and cellular phospholipid linings rich in phosphatidylcholine (PC) in the gel phase (Lβ′ ),
which constitute a protective barrier of the GI mucosa against the attack of luminal acid (H+).
The mitochondria outer and inner membranes (OMM and IMM) containing typical crista and
contact points rich in bilayer prone phospholipids (e.g., PC) that produce lamellar phases (Lα) and
non-lamellar prone lipids (e.g., Cardiolipin (CL) and phosphatidylethanolamine (PE)) that produce
inverted hexagonal phases (HII) are also represented. (B) Schematic representation of GI topical damage
depicting the disruptive effect of non-steroidal anti-inflammatory drugs (NSAIDs) on the GI protective
phospholipid lining. On the right are represented the ossible mechanisms by which NSAIDs cause
mitochondrial toxicity: inhibition of respiratory chain; i hibition of ATP synt ase and tra slocase;
blockage of cation transporters; and membrane permeabilization with the formation of membrane
permeability transition pores (MPT).
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The topical effect of NSAIDs and their role in causing GI damage can be explained by a biophysical
interaction between drug molecules and phospholipids. GI cells are protected by a mucus layer that
serves as a matrix of phospholipids of which phosphatidylcholines represent a prominent component.
The phospholipid lining provides a resistant gel layer with a non-wettable hydrophobic surface that
protects the epithelium from luminal acid [7–10,21,22]. NSAIDs interact with the phospholipid lining
of the GI mucus layer and the cell surface phospholipid bilayer, compromising their biophysical
integrity. This increases the mucus layer wettability and leads to GI mucosal exposure to luminal
acid and other aggressive agents (pepsin, bacteria and bile) with the consequent development of
erosions [6,21] (Figure 1). Although several studies have been conducted to evaluate the role of COX
selectivity in GI toxicity of NSAIDs, less attention has been paid to the biophysical effects of the
NSAIDs-membrane interaction, knowledge of which is essential to understand these drugs’ GI topical
effect [6,8–10,21]. Only recently, studies have focused on the biophysical factors that may account for
the apparent low ulcerogenicity of some NSAIDs in comparison with others that demonstrate higher
toxicity. Studies involving membrane model systems mimicking the phospholipid lining of the GI
protection barrier have reported fluidizing and disordering effects of NSAIDs, indicative of their GI
toxicity. This was the case with indomethacin, acemetacin, piroxicam, tolmetin, celecoxib, aspirin,
naproxen and ibuprofen [10,23–30], which were all able to destabilize the gel phase of the GI mimetic
phospholipid lining. By contrast, nimesulide and etoricoxib, which are safer at the GI level, revealed
the least perturbing effects on the lipid gel phase and on the lipids extracted from the GI brush border
membrane, respectively [23,30,31].
Furthermore, NSAIDs also demonstrated a capacity to interfere with the mitochondrial function
through several pathways as an additional role contributing to NSAID’s GI toxicity (Figure 1). NSAIDs’
uncoupling effect of oxidative phosphorylation or inhibition of electron transport in mitochondria
causes a reduction of adenosine triphosphate (ATP) cellular levels, damaging the intercellular junctions
in the GI tract, increasing mucosal permeability, and ultimately causing apoptosis and GI cell
death [6,11]. In this regard studies performed in isolated mitochondria reported that DCF can act as
an uncoupler agent of mitochondrial oxidative phosphorylation and can instigate the aperture of a
channel-type structure in the inner mitochondrial membrane called the mitochondrial permeability
transition pore (MPT).
MPT results in the dissipation of the proton gradient across the inner mitochondrial membrane
and, consequently, in the collapse of the transmembranar potential (i.e., membrane depolarization)
and in the decrease of ATP synthesis [18,19,32,33]. DCF can inhibit mitochondrial ATP synthesis at a
therapeutic relevant concentration [18,34] and some authors demonstrated time and dose dependent
effects of DCF in the capacity to perturb mitochondrial function [18,35,36]. Additionally, DCF
interacts with several ion channels from different cells, including voltage-gated Na+, Ca2+ channels,
ligand-gated K+, transient receptor potential (TRP), and other cation nonselective channels affecting
the ion homeostasis in the mitochondrial membrane [37]. Related to this effect, a more pronounced
mitochondrial swelling (i.e., MPT) of DCF has been demonstrated in the presence of Ca2+ [19].
Although disruption of the mitochondrial function is recognized as a common occurrence among
the adverse effects of DCF, its in vivo mechanism is not yet fully understood [38] and studies concerning
the biophysical topical effect of DCF at the mitochondrial membrane level are required. Indeed,
the mitochondrial bioenergetic function can also be impaired by membrane biophysical changes that
may affect cardiolipin (CL), thereby inhibiting specific transporters in the mitochondrial membrane [36].
CL is a signature phospholipid of the inner mitochondrial membrane (IMM) capable of forming
lamellar and non-lamellar lipid structures. This polymorphic capability is essential to the normal
functioning of the IMM so drug-induced changes in this ability are possibly harmful to the normal
functioning of membrane bound proteins [39–42].
Some studies have been performed to investigate the molecular interactions between DCF and
lipid membranes [25,43–45]. The results of these studies suggest the facility of DCF to penetrate and
interact with lipid membrane environments and, hence, its ability to modify membrane biophysical
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properties with impacts on physiological membrane-related functions. The studies reported are very
relevant for a broad understanding of DCF–membrane interactions; however, lipophilicity, acid–base
properties, the lipid phase, and the composition of the membrane models used play a determinant role
in the drug-membrane interactions [24,46,47]. A more specific biophysical approach contemplating
these parameters to study DCF effects on phosphatidylcholine-rich GI linings is missing in the literature.
Furthermore, previously reported in vitro studies performed in rat and human cellular mitochondria
have proved toxicity induced by DCF and suggested that DCF’s functional groups (probably carboxylic
acid) might play a fundamental role in such effects [18,36,48]. Nevertheless, to our knowledge, there
are no biophysical studies concerning the interaction of DCF with CL-rich membrane models that can
confirm this assumption and reinforce the topical aspect of DCF mitochondrial toxicity.
In summary, the main aim of this work is to contribute to a better understanding of DCF’s GI
topical toxicity using relevant pH conditions and membrane models that mimic the biophysical and
chemical environment encountered by the drug: (i) in the phospholipid lining protective barrier of GI
mucosa; and (ii) in the IMM. Several biophysical techniques were used to provide a molecular, thorough
study: derivative spectrophotometry to evaluate DCF’s distribution at the membrane; steady-state
and time-resolved fluorescence to predict DCF’s location at the membrane; fluorescence anisotropy,
differential scanning calorimetry (DSC) and dynamic light scattering (DLS) to assess DCF’s effect at
membrane microviscosity; calcein leakage studies to study DCF’s effects on membrane permeability;
and synchrotron small- and wide-angle X-ray scattering studies (SAXS and WAXS, respectively),
to evaluate the effects of DCF at the membrane structure. The gathered results confirm DCF’s effects
on the impairment of membrane biophysical properties, which are in line with the reported effects
on membrane fluidity, transmembrane potential, and protonophoric activity, and have an impact on
physiological membrane-related functions and on DCF’s local gastric toxicity.
2. Results
2.1. Diclofenac Distribution Coefficient in a Membrane/Aqueous System
The first physicochemical property of NSAIDs that provides solid evidence to support the
distribution of these drugs within the PC of the GI protective layer is the distribution coefficient (Kd)
between lipid/aqueous phases, which allows evaluation of the drug’s distribution in the hydrophobic
and hydrophilic microenvironments [46]. Accordingly, the Kd of DCF was determined in LUVs (large
unilamellar vesicles) of 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) at pH 5.0 and at 37 ◦C
by derivative spectrophotometry. The membrane model system was chosen to mimic the PC lining
present in both extracellular and membrane barriers (Figure 1) [6,10]. The studies were performed at
acidic pH of 5.0 to mimic the average pH values encountered by these drugs in the upper parts of the
GI where drug absorption occurs [46]. The pH value of 5.0 was chosen based on the posologic regimen
of NSAIDs that recommends administration after meals [49]. Thus, this is the value reported to be the
pH of luminal gastric and upper intestinal segments in a fed state [46]. Examples of the absorbance
spectra and subsequent derivative method for data analysis are presented in Figure 2.
From the absorbance spectra of DCF experimentally obtained for increasing concentrations of
LUVs of DMPC (Figure 2A), the third derivative spectra were calculated (Figure 2B), as this eliminates
the effect of Rayleigh dispersion, which is higher for smaller wavelengths [50]. Third derivative spectra
analysis eliminates light-scattering interference and improves spectral resolution, enhancing details of
DCF–lipid interaction. Indeed, at the derivative peaks, it is possible to observe a shift of λ (of about
10 nm; see Table 1), indicative of DCF distribution into environments of lower polarity (distribution of
DCF into the lipid phase) [51] with a decrease in the intensity of the bands as the lipid concentration
increases. Isosbestic points are also observed, indicating the existence of a balance between two DCF
forms (interacting with the lipid medium and free in aqueous buffered medium) and the eradication
of light-scattering interference [50]. Using maximum or minimum values from derivative spectra
(e.g., 321 nm), data were plotted against the respective DMPC concentration (Figure 2C) and the
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resulting data points were fitted to Equation (1) (Figure 2C, black line). From that fitting, Kd values
were calculated (Table 1).Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  5 of 26 
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Table 1. Distribution coefficients of DCF obtained in a biphasic membrane/aqueous system.
pH ∆λ Kd Log Kd
3.0 26,00 3000 4.41 ± 0.05 1,* *
5.0 319–328 6970 379 2 3.84 ± 0.02 2,***
7.4 1200 ± 100 1 3.08 ± 0.04 1,***
1 Values reported in [43] calculated by derivative spectrophotometry in LUVs of egg-phosphatidyl choline (EPC).
2 Values determined by derivative spectrophotometry in LUVs of DMPC. Results are the mean± standard deviation
of at least three independent measurements and comparisons were performed using one-way ANOVA with the
Tuk y-Kramer post-test; *** indicates a valu of p < 0.001, which was considered statistically significant.
For comparison, in Table 1 are presented the reported Kd values in biphasic membrane/aqueous
systems at two other pH values: 3.0 and 7.4 [43]. The values are dimensionless and resulted from the
correction of the lipid molar volume of each model system so that they can be compared.
The Kd of DCF into PC membranes was shown to be deeply dependent on the pH values.
This different distribution of DCF should be attributed to the different ionization state of the drug and
reflects the importance of studying NSAID-lipid interaction using lipid model systems at different
relevant physiological pH values. The pKa of DCF has been reported to be 3.97 ± 0.04; thus, at pH 3.0
(pH < pKa), the drug molecule is in the neutral protonated form and the distribution within the PC
membranes is maximum (Log Kd = 4.41 ± 0.04) [43]. At pH values higher than the pKa (pH 5.0 and
7.4), the drug distribution decreases as the pH increases. This is due to the presence of negatively
charged ionic forms of DCF, which, because they are more polar, are less distributed in the lipid media
than the neutral forms. Furthermore, according to the Henderson-Hasselbach equation, at pH 7.4,
the concentration of negatively charged DCF is 2692 times higher than the concentration of the drug’s
neutral form (which is almost nonexistent), whereas, at pH 5.0, the concentration of the negatively
charged DCF is 10 times higher than the concentration of the drug’s neutral form. These differences
confirm that the DCF neutral form is more distributed within PC membranes as well as indicate that
DCF can be distributed within PC membranes even at pH 7.4, when its ionization is practically 100%.
In this latter case, drug distribution within lipid membranes should also be ruled by electrostatic
interactions established between negatively charged carboxyl groups of DCF and PC’s positively
charged choline groups.
Int. J. Mol. Sci. 2018, 19, 3411 6 of 26
2.2. Diclofenac Location in a Membrane/Aqueous System
After quantifying DCF distribution between the lipid and aqueous phases of the membrane model
system, it is important to assess where the drug will be most likely located within the lipid phase of
the membrane. Assessing drug location at mimetic systems of the GI protective layer will allow us
to understand if the drug is more superficially bounded in the PC headgroups or if it is more deeply
buried at the hydrophobic microenvironment of the PC acyl chains.
For this purpose, it is possible to label the lipid model system with fluorescent extrinsic fluorophores,
such as N,N,N-Trimethyl-4-(6-phenyl-1,3,5-hexatrien-1-yl)phenylammonium p-toluenesulfonate
(TMA-DPH) and 1,6-Diphenyl-1,3,5-hexatriene (DPH) fluorescent probes. When incorporated in the
membrane, the position of these probes is known, and they work as molecular rulers capable of labeling
different depths of the lipid bilayer (Figure 3A). TMA-DPH possesses a cationic group that anchors the
probe at the polar headgroup region of the membranes being described as a reporter of more ordered
shallow regions of the bilayer (glycerol backbone and upper segments of the phospholipid acyl chains)
while DPH is used to report deeper regions of the phospholipid acyl chains [52–54].
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fluorescence quenching of the probe TMA-DPH and DPH induced by increasing DCF concentrations
and determined by steady-state and lifetime measurements at 37 ◦C. From the Stern-Volmer plots
and using Equation (2), it was possible to determine the Stern-Volmer constant values (KSV) for both
probes at several temperatures (Supplementary Table S1) thereby defining the type of quenching
mechanism that was further confirmed by lifetime measurements. In the case of the static quenching
mechanism, lifetime values did not change and τ0/τ = 1, as observed in Figure 3C for TMA-DPH.
Accordingly, it was possible to conclude that DCF induced a fluorescence quenching of TMA-DPH by
a static mechanism while DPH was quenched by the drug by a collisional mechanism.
Although KSV values are used to evaluate the extension of the quenching for each probe
individually, the comparison of quenching effects using the two different probes (TMA-DPH and DPH)
requires the calculation of the bimolecular quenching rate constant (Kq) that indicates the accessibility
of the probes to the quencher (DCF), thereby eliminating specificities related with differences in probes’
fluorescence lifetime in the absence of the quencher. The Kq constants resultant from DCF quenching of
TMA-DPH and DPH fluorescence when the probes were incorporated in a PC mimetic GI model were
calculated for two lipid membrane phases (Table 2). The lamellar gel phase (Lβ′ ) is relevant to mimic
the gel-ordered phase of the GI phospholipid lining, while the lamellar fluid phase (Lα) is considered
the most predominant phase in cellular membranes and can also mimic disordered domains on a
damaged GI phospholipid lining [7,9,10].
Table 2. Bimolecular quenching rate constant (Kq) obtained from measurements of fluorescence
quenching of TMA-DPH and DPH by DCF in two membrane model systems at pH 5.0 (in the case of
GI mimicking) and pH 7.4 (in the case of IMM mimicking).
GI mimicking: PC Membrane Model
Probe Lipid Phase Kq × 109 (M−1·s−1)
TMA-DPH
Lβ′ 2.63 ± 0.03
Lα 2.30 ± 0.09 ***
DPH
Lβ′ 0.37 ± 0.02 ***
Lα 1.34 ± 0.04 ***
IMM mimicking: DOPC:DOPE:CL (1:1:1) Membrane Model
Probe Lipid Phase Kq × 109 (M−1·s−1)
TMA-DPH
Lα 1.24 ± 0.06 ***
HII 2.90 ± 0.23 ***
DPH
Lα 0.73 ± 0.04 *
HII 1.87 ± 0.29 ***
Lα, Lβ′ and HII stand, respectively, for lamellar fluid phase, lamellar gel phase, and inverted hexagonal phase.
Results are the mean ± standard deviation of at least three independent measurements and comparisons were
performed using one-way ANOVA with the Tukey-Kramer post-test for the following paired observations: (1) fluid
phase of TMA-DPH or DPH vs. gel phase of TMA-DPH or DPH in GI mimicking (***, p < 0.001); (2) gel phase
of DPH vs. gel phase of TMA-DPH in GI mimicking (***, p < 0.001); (3) fluid phase of DPH vs. fluid phase
of TMA-DPH in GI mimicking (***, p < 0.001); (4) inverted hexagonal phase of TMA-DPH vs. fluid phase of
TMA-DPH in IMM mimicking (***, p < 0.001); (5) inverted hexagonal phase of DPH vs. fluid phase of DPH in IMM
mimicking (***, p < 0.001); (6) fluid phase of DPH vs. fluid phase of TMA-DPH in IMM mimicking (*, p < 0.05);
(7) inverted hexagonal phase of DPH vs. inverted hexagonal phase of TMA-DPH in IMM mimicking (***, p < 0.001);
(7) fluid phase of TMA-DPH in IMM mimicking vs. fluid phase of TMA-DPH in GI mimicking (***, p < 0.001);
and (8) fluid phase of DPH in IMM mimicking vs. fluid phase of DPH in GI mimicking (***, p < 0.00)1. DOPC,
DOPE, and CL are 1,2-dioleoyl-sn-glycero-3-phosphocholine and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine,
and Cardiolipin, respectively.
The analysis of Kq values obtained in the GI mimetic model indicates that: (i) DCF can quench
the fluorescence of both probes; (ii) in both lipid phases, Kq values are significantly higher for the
TMA-DPH probe; and (iii) for the probe TMA-DPH, the Kq values are higher in the Lβ′ phase in
contrast to those observed for the probe DPH. These results allowed us to propose that DCF orientation
is parallel to the phospholipid molecules with the ionized negatively charged carboxyl group anchored
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at the polar PC headgroup region (Figure 3A). The presence of three quencher moieties in the DCF
molecule (Figure 3D) justifies that at this proposed orientation the drug is accessible and quenches
both probes. However, DCF ionization at pH 5.0 dictates its anchoring to the polar regions of the lipid
membrane, which is reflected in higher quenching efficiencies of TMA-DPH. The higher accessibility to
TMA-DPH is further confirmed by the static quenching mechanism observed for this probe, which fits
well with our predicted location (Figure 3A). According to this prediction, the dichlorophenyl group
of DCF may establish a stacking interaction with the phenyl group of TMA-DPH, which, by being
also anchored to the polar headgroup region, has a shallower location than DPH (Figure 3A). Indeed,
this type of chemical-stacking interaction has been described as responsible for static quenching
mechanisms [55]. It is also relevant to say that the Lβ′ phase, in possessing better lipid packing, may
constitute a hindering factor to the drug accessibility to the probes. Nonetheless, for the TMA-DPH
probe, the Kq values were higher in the Lβ’ phase (Table 2), highlighting the capacity of DCF to
penetrate the phospholipid gel lining protective of the GI tract and corroborating the drug’s potential
topical GI toxicity.
As described for other NSAIDs, after DCF penetration in the phospholipid gel lining of the GI tract,
the drug can diffuse across gastric mucosal epithelial cell membranes into the cytoplasm, where pH is
neutral and where it finds another target of NSAIDs’ topical effect: mitochondria [6,11,56]. NSAIDs’
uncoupling effects at the mitochondria result from multiple pathways, of which the least explored is
their molecular biophysical interaction with the mitochondria membrane [57,58]. In the case of DCF,
there are no studies concerning this approach and thus we propose using an IMM mimetic model
to investigate how DCF distributes at the mitochondrial-enriched CL membranes. To also appraise
DCF distribution in lipid phases characteristic of IMM, quenching effects were evaluated when the
former fluorescent probes were incorporated in liposomes composed of a mixture of DOPC:DOPE:CL
(1:1:1). Quenching assays were performed at pH 7.4 characteristic of cytosolic mitochondria and
at different temperatures at which the lamellar (Lα) or inverted hexagonal (HII) arrangement of
lipids prevailed [58–60]. These different lipid phases mimic the two morphological hallmarks of
mitochondria, namely cristae of the IMM (rich in CL lamellar fluid lipid structures) and contact sites
between the IMM and the outer mitochondrial membrane (OMM) that are likely to involve nonlamellar
CL enriched lipid structures [40]. Once more, in this lipid model system, and at any of the lipid phases,
DCF was able to quench both probes; the resultant Kq values are presented in Table 2. In this case,
the analysis of Kq values indicates that the quenching is higher for the TMA-DPH probe, reflecting,
as previously observed, a preferential orientation of DCF molecules anchored to the polar headgroup
regions of the lipid arrangements. Moreover, DCF has higher quencher efficiencies in conditions at
which the mixture of lipids is preferentially organized in the HII phase. In fact, at this phase and for
both probes, Kq values are about 40% higher. These findings suggest a preferential distribution of
DCF through the HII contact sites of mitochondria membrane. Once the nonlamellar arrangements
are reported as essential for normal functioning of mitochondria, the preferential distribution of
DCF within these nonlamellar arrangements may be potentially detrimental to other mitochondrial
membrane-bound structures [40] and might be related to the MPT effects reported for this drug.
2.3. Effects of Diclofenac in the Microviscosity and Permeability of the Membrane
Besides studying how DCF distributes within a membrane model mimetic of GI protective
lining, it is also important to study how the drug can affect the biophysical integrity of such lining
with consequent exposure of mucosa cells to aggressive agents, resulting in ulcer formation and
bleeding [10]. Evidence has supported the concept of NSAID-induced perturbation of membrane
biophysical properties (e.g., by decreasing membrane microviscosity or by altering lipid structure
and packing) translating into an increase in the permeability of biological membranes, sometimes
with fusion effects [10,21,23,25,27,28,45,57,61]. In this context, the effects of DCF in the thermotropic
behavior of PC model systems (LUVs of DMPC) used to mimic the PC-enriched GI lining were
evaluated at pH 5.0 by DLS and DSC. Evaluation of the thermotropic behavior of lipid membranes
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by DLS is based on the fact that the measured count rate (average number of photons scattered by
the liposomes analyzed detected per second) reflects changes in the optical properties of lipid vesicles
with temperature variations. Accordingly, lipid systems in more ordered phases induce higher light
scattering and lead to higher count rate values than the fluid lipid systems [29,62]. The count rate of
DMPC liposomes measured as a function of temperature in the absence and presence of DCF at pH 5.0
is shown in Figure 4.
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(Tp = 15.4 ± 0.4) from the Lβ’ to the ripple phase (Pβ’); and (ii) main phase transition temperature
(T = 22.8 ± 0.2) from the Pβ’ to the Lα phase. When DCF is added to the lipid system, it abolishes the
Tp and does not affect Tm but reduces the cooperativity of the main phase transition. The abolishment of
p indicates interactions established betwee DCF and the polar headgroups of PC membranes [63] and
corroborates the shallow l cation of this NSAID predicted by fluorescence quenching. The bserved
decrease of the cooperativity of the main transition is also in agreement with the DCF location within
the polar headgroup region since the cooperative nit that undergoes the transition is largely regulated
by the interaction in the carbons C1–C8 of the acyl chai s [64]. M reover, despite not changing Tm,
DCF has a significant effect in reducing DMPC membrane microviscosity in the gel and fluid phases,
as observed b the significant decrease of count rate values in both phases. This indicates that, in the
presence of DCF, the lipid bilayer system becomes more fluid and thus less capable of scattering
light. DSC measurements confirmed the overall concl sions obtai ed with DLS (Supplementary
Figure S1). From DSC thermogram, it was possible to conclude that DCF abolished the pre-tra sition
pe k and reduced the coop rativity f th ph se transition with ut significantly changing enthalpy.
These observations reinforce that the predicted drug location is closer to the queous lipid interface.
However, with this technique it was possible to observe a slight reduction (0.34 ◦C) of Tm when DCF
was incorporated in the lipid system. Alt ough to a smaller extent, this observation agrees wit
previous DSC studies that account for a DCF-induced disordering effect t DMPC membranes [25].
Indeed, Manrique-Moreno and co-workers observ that the addition of increasing concentrations
of DCF to the lipid system i duced the disappearance f t e ripple phase and a shift of Tm for lower
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temperatures. The extent of this shift was about 2 ◦C for a lipid:drug molar ratio of 1:0.1 at pH 7.4 [25].
It should be noted that we have tested a significantly lower lipid:drug molar ratio (1:0.03) to observe
an effect at DCF concentrations closer to therapeutic levels, and we have studied the drug–lipid
interaction at pH 5.0 to mimic the pH of the PC lining of the luminal gastric and upper intestinal
segments in a fed state.
To study how DCF can affect the lipid dynamics and phospholipid acyl-chain packing of the
mitochondrial membranes, fluorescence anisotropy and calcein release studies were performed by the
addition of increasing drug concentrations to an IMM mimetic model made of liposomes composed of
a mixture of DOPC:DOPE:CL (1:1:1) at pH 7.4. In the case of steady-state anisotropy measurements,
the rotational correlation time (θ) was calculated for the same fluorophores used in fluorescence
quenching studies (TMA-DPH and DPH), incorporated in the IMM mimetic model at different
temperatures at which the Lα or HII arrangement of lipids prevailed (Figure 5A).
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Since θ gives information about the probe motion, it will report the fluidity of the surrounding
environment of the probe. Therefore, if DCF added to the lipid model system affects the membrane
fluidity, it can alter the probe motion, producing changes in θ values. Accordingly, as shown in
Figure 5A, it is possible to conclude that DCF promotes a significant fluidizing effect at the polar
regions of the L phases characteristic of IMM cristae. However, to a lesser extent, DCF also promotes a
fluidizing effect at the polar headgroup regions of the HII phases characteristic of contact sites between
IMM and OMM. However, at the inner regions of the Lα and HII phases, DCF has a negligible effect
on hydrocarbon chain packing. This was expected given the preferential distribution of DCF in the
headgroup region confirmed by fluorescence quenching, DSC, and DLS studies.
Another way of studying if DCF affects the biophysical integrity of the mitochondrial
membrane is the study of membrane permeability by calcein release. Liposomes of DOPC:DOPE:CL
(1:1:1) simulating the Lα phase of the IMM were loaded with calcein at a concentration where
self-quenching of this probe occurs. After addition of DCF to the membrane mimetic system, membrane
permeabilization was followed by calcein release, measuring the fluorescence intensity increase.
As shown in Figure 5B, DCF increased the permeability of the membrane system assayed in a
dose-dependent manner, reaching 25% of calcein leakage at the maximal concentrations tested.
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2.4. Effects of Diclofenac in Lipid Packing and Membrane Structure
Membrane fluidity is a complex biophysical aspect of biomembranes that encompasses a
combination of dynamic and orientational properties of the constituents of membrane lipid bilayer.
When studying the effect of drugs on the fluidity of membrane lipid model systems, it is therefore
necessary to analyze different properties, such as membrane microviscosity and permeability, as well
as membrane structure and lipid packing parameters [65,66]. In this regard, the effects of DCF in
different DPPC (1,2-dipalmitoyl-sn-glycero-3-phosphocholine) lipid phases were evaluated by SAXS
and WAXS diffraction patterns providing information on the bilayer structure and lipid packing
through the respective measurement of long and short spacings (d values). The studies were conducted
in a DPPC lipid model at pH 5.0 to mimic the PC content of the phospholipid GI lining, particularly
given palmitoyl derivatives are associated with the integrity of the protective GI barrier. The studies
were performed in temperatures ranging from 20 to 50 ◦C to comprehend the different lipid phases;
however, special attention has been paid to the Lβ’ representative of the GI phospholipid lining [7,9,10].
Typical SAXS and WAXS patterns were obtained for Lβ’, Pβ’, and Lα phases of fully hydrated
DPPC at pH 5.0 in good agreement with the literature [26]. From the SAXS patterns of DPPC,
the lamellar long spacing was determined in each lipid phase (Supplementary Table S2) and the long
spacing values are represented as a function of temperature in Figure 6A.
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74.0 ± 0.5 Å in the Lα phase (Supplementary Table S2). The profile obtained for the long-spacing 
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Figure 6. Long and short spacing obtained, respectively, by SAXS (A,C) and W XS (B,D) measurements
of DPPC ultilayers made at several temperatures and at pH 5.0 in the abse ce (open symbols)
and in the presence (closed symbols) of DCF. Values are presented as average spacin ± standard
deviation calculated from all diffraction peaks. Dashed lines are guidelines only, and star symbols
are temperatures at which no Bragg peaks appear in the WAXS region. Lβ, Lβ’, Pβ’, and Lα stand
for lamellar gel phase (β stands for untilted and β’ stands for tilted), ripple phase, and lamellar fluid
phase, respectively.
Int. J. Mol. Sci. 2018, 19, 3411 12 of 26
In the Lβ’ phase, the bilayer thickness, including a water layer between the bilayers, was
determined to be 65.4 ± 0.5 Å (see also Supplementary Table S2), similar to values that have been
reported in the literature [26]. On heating, the spacing increases to 67.0 ± 0.5 Å in the Pβ’ phase and to
74.0± 0.5 Å in the Lα phase (Supplementary Table S2). The profile obtained for the long-spacing values
as a function of temperature (Figure 6A) indicates a transition to the Lα phase at ca. 42 ◦C, in agreement
with the main phase transition found for DPPC [23,26,67]. Deconvolution of the WAXS patterns
obtained at the Lβ’ phase gives the lattice constants of two peaks characteristic of an orthorhombic
lattice with tilted chains, i.e., short spacing values of 4.05 ± 0.05 Å and 4.17 ± 0.05 Å (Figure 6B and
Supplementary Table S2), which are also in good agreement with the results described for DPPC lipid
systems at pH = 5.0 [26]. Increasing temperature leads to a decrease of the lattice distortion, and at
ripple phase, the two Bragg peaks of the orthorhombic lattice come closer together. At temperatures
≥42 ◦C, the WAXS peaks were too broad to be assigned, confirming the main phase transition found
for the lipid system in the SAXS measurements and literature [23,26,67].
The diffraction peaks of the DPPC system in the absence of the drug present a small full width
of the peaks at one-half of their intensity (fwhm), indicating a good correlation between the bilayers
(see values of correlation length, ξ, in Supplementary Table S2). Such a correlation is profoundly
reduced by the addition of DCF to the lipid system, manifesting the disturbance effect of this NSAID
on the membrane structure (Supplementary Table S2). The broadening of the characteristic DPPC
Bragg reflections in the case of the DCF loaded membrane model systems (Supplementary Figure
S2) indicates the breakdown of the multilamellar correlation due to the inclusion of the drug [65].
The profile of the long-spacing values as a function of temperature obtained for DPPC systems
containing DCF (Figure 6C) indicates a main transition temperature occurring at ca. 40 ◦C, confirmed
by the short-spacing values as a function of temperature (Figure 6D). Accordingly, at temperatures
≥40 ◦C, the WAXS peaks were too broad to be assigned, confirming the presence of a Lα phase.
Figure 6C also shows an increase in the thickness of the bilayer plus the aqueous layer at the entire
range of temperatures assayed in comparison to the same profile obtained for the lipid membrane
system without the drug (Figure 6A). At temperatures corresponding to the more disordered phase
(Lα fluid phase), this increase of the long-spacing values was 2.3 ± 0.2 Å, which may be attributed to
an increase in the hydration layer. Indeed, the location of the drug in the polar headgroups can modify
the surface-bond water molecules in the bilayer, as previously stated to happen with DCF and other
NSAIDs in a DSC study made in DMPC model systems at physiological pH [25].
At temperatures corresponding to the more ordered phases of DPPC (gel and ripple phase),
an average increase in the long spacing of 7.3 ± 1.6 Å was observed upon DCF addition in comparison
to that observed for the lipid membrane system without the drug. The increase of d values at the lipid
ordered phases should be also caused by the interaction of DCF with the polar headgroups of the lipid
membrane. Such interactions could reduce the effective area requirement of the PC headgroups by
two possible effects: (i) reduction of the chain’s tilt angle; and/or (ii) increasing of the water layer.
We can thus start to analyze if this increase in the d values is coherent with a tilt angle change by
some simple deductions. In the gel phase, the hydrocarbon chains of the fatty acids constituting the
phospholipids are rigidly packaged, with their C–C bonds in an all-trans conformation, which allows
the accommodation of the hydrophobic chains in a minimum volume. These all-trans C–C bonds
organized in CH2 groups in hydrocarbon chains are at an interval of 1.26 Å, while the distance between
the C–C bonds in the terminal CH3 group is 1.46 Å [68]. Thus, in the case of DPPC, which consists of
two chains of palmitic acid of 16 carbon atoms, the length occupied by them will be 40.4 Å. This is
the length corresponding to the stretched hydrocarbon chains (without tilt) of a DPPC molecule. It
is known, however, that in the gel phase of DPPC bilayers, the hydrocarbon chains are tilted at an
angle, θtilt, of approximately 32◦ [69] relative to the plane of the membrane, to fill the created free
space by polar groups and to increase the proximity between adjacent chains, maximizing van der
Waals interactions [69]. Thus, given that the chains are tilted, the thickness of the bilayer will not be
40.4 Å, but rather 40.4 × cos(32◦) = 34.3 Å, and the difference between the thickness corresponding
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to the stretched and tilted chains is given by 40.4 − 34.3 = 6.1 Å. Therefore, the average increase in d
values obtained at the ripple and gel phase of DPPC upon addition of DCF is similar (within the error)
to what it is expected for chains’ untilting. This conclusion can be further confirmed by comparison of
WAXS patterns obtained for DPPC and DPPC upon DCF addition (Figure 7A). The chain packing of
DPPC bilayers is significantly influenced by DCF by the appearance of one Bragg peak (Figure 7A,
upper diffraction WAXS pattern) instead of the typical two Bragg peaks (Figure 7A, lower diffraction
WAXS pattern). This indicates a change from the orthorhombic unit cell of tilted chains to a hexagonal
packing of non-tilted chains, which correlates well with the already-discussed increase in d values
observed in SAXS.
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3. Discussion 
Despite being widely prescribed, DCF has been associated with cases of severe GI injury, 
especially when administrated on a daily basis for the treatment of chronic situations [4]. 
To investigate the effects of DCF on the GI phospholipid lining, we have methodically examined 
the interaction between DCF and PC membranes at relevant lipid membrane phases using a selection 
of biophysical techniques that offer complementary information. These techniques clearly proved, at 
a pH of 5.0, that DCF presents a noticeable distribution at the membrane phase despite being partially 
ionized. Furthermore, we have concluded that the chemical association between DCF and the 
membrane phospholipids is clearly pH dependent, highlighting the importance of the pH of studies 
in understanding NSAID–PC interactions. This pH dependence is consistent with the findings 
reported in studies involving other NSAIDs (e.g., aspirin, ibuprofen, naproxen, tolmetin, 
indomethacin, nimesulide, acemetacin, piroxicam, meloxicam, and celecoxib) [7,10,27–29,71]. 
Besides quantifying DCF membrane distribution, we have also been able to propose a molecular 
orientation of this NSAID within the lipid bilayer. DCF is located at the phospholipid headgroup 
region, and probably anchored at the choline level by an electrostatic interaction with the negatively 
charged carboxylate moiety. DCF preferential location at the membrane polar region was also 
observed by Ferreira et al., who determined the distribution of the drug in egg lecithin membrane 
models by spectroscopic techniques while calculating surface concentrations of the drug by zeta-
Figure 7. tterns recorded in static exposures at 20 ◦C and at pH 5.0 for multilayers
of DPPC in the absence (lower figure) and pr sence of DCF. Solid red lines give the best fit of the
Lorentzian’s anal si i . ( ) Sche atic representation of the effect of
DCF penetrating the e r i l ss of tilt angle with consequent increase
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Figure 7B illustrates DCF interaction with DPPC at the gel phase possibly inducing a change
of the polar headgroups’ orientation in a perpendicular position to the bilayer plane, reducing the
area requirement of the headgroups and allowing the chains to be oriented in an upright position.
This schematic location of DCF in the headgroup region is further confirmed by the calculation
of the cross-sectional area (A0) of a single aliphatic chain obtained from WAXS patterns in the gel
phase (Supplementary Table S2). A0 of 20.1 Å2/aliphatic chain was determined for the DPPC, which
is in good agreement with the previously reported [23]. Addition of DCF to DPPC reduces A0 to
19.0 Å2/aliphatic chain, ruling out the possibility of penetration of DCF within the aliphatic core of the
membrane as previously observed for other drugs [70].
3. Discussion
Despite being widely prescribed, DCF has been associated with cases of severe GI injury, especially
when administrated on a daily basis for the treatment of chronic situations [4].
To investigate the effects of DCF on the GI phospholipid lining, we have methodically examined
the interaction between DCF and PC membranes at relevant lipid membrane phases using a selection
of biophysical techniques that offer complementary information. These techniques clearly proved,
at a pH of 5.0, that DCF presents a noticeable distribution at the membrane phase despite being
partially ionized. Furthermore, we have concluded that the chemical association between DCF and
the membrane phospholipids is clearly pH dependent, highlighting the importance of the pH of
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studies in understanding NSAID–PC interactions. This pH dependence is consistent with the findings
reported in studies involving other NSAIDs (e.g., aspirin, ibuprofen, naproxen, tolmetin, indomethacin,
nimesulide, acemetacin, piroxicam, meloxicam, and celecoxib) [7,10,27–29,71].
Besides quantifying DCF membrane distribution, we have also been able to propose a molecular
orientation of this NSAID within the lipid bilayer. DCF is located at the phospholipid headgroup
region, and probably anchored at the choline level by an electrostatic interaction with the negatively
charged carboxylate moiety. DCF preferential location at the membrane polar region was also observed
by Ferreira et al., who determined the distribution of the drug in egg lecithin membrane models
by spectroscopic techniques while calculating surface concentrations of the drug by zeta-potential
measurements [45]. In another study, Manrique-Moreno et al. presented an interesting contribution
to understanding the membrane-activity of some NSAIDs such as DCF, ibuprofen, and naproxen,
using different spectroscopic and thermodynamic techniques. Regarding DCF, this study proposed a
location in closer proximity to the phosphate region [25]. The observations described in these studies
are thus consistent with our DCF proposed location at the Lα phase. Additionally, our quenching
studies also support the hypothesis that DCF can penetrate the GI protective phospholipid gel lining
as the drug was able to reach the membrane-located fluorophores even at the more ordered Lβ’ phases.
Interestingly, the quenching efficiency of the membrane fluorophore was significantly higher in the gel
phase, indicating that this more ordered phase does not hinder DCF membrane penetration, which is
consistent with the proposed topical injury to the GI mucosa.
Direct techniques (DLS and DSC) that do not require the insertion of fluorophores in the membrane
confirmed DCF location at the headgroup lipid region and suggested a membrane fluidizing effect of
the drug. SAXS and WAXS studies confirmed DCF’s strong effect on membrane structure observed by
loss of correlation between the lipid bilayers and membrane-fluidizing effect promoted by the drug.
Additionally, the measured lipid spacings in the gel phase indicated that DCF penetrates at the lipid
polar region, allowing the phospholipid acyl chains to lose their tilt. In vivo, these changes in lipid
packing can open spaces for the passage of gastric acid and other aggressive factors that may injure
the GI mucosa (as schematically represented in Figure 1B).
In susceptible patients where the phospholipid protective lining may have lost part of its gel
integrity arrangement and may present fluid domains, DCF is also able to induce structural changes.
At this fluid domains DCF increases the hydration layer, which is consistent with its capability to
attenuate the hydrophobic barrier properties of the upper GI tract. Such a biophysical effect of
increasing the GI phospholipid lining wettability has been described as able to promote the back
diffusion of luminal acid into the mucosa and the development of erosions [72].
In agreement with the current work, some studies confirmed the disordering and/or fluidizing
effect of DCF in lipid membranes and linked the results to other toxic events. Suwalsky et al. assessed
the influence of DCF in a class of lipids found in the outer moiety of the erythrocyte membranes
and in isolated human erythrocytes membranes using X-ray diffraction, fluorescence spectroscopy,
and scanning electron microscopy [45]. The authors concluded that DCF interacted with red cell
membranes, inducing a membrane disordering effect and changes in normal cellular morphology,
which could presumably contribute to DCF toxicity effects [45]. A membrane disordering effect induced
by DCF was also observed by Souza et al. [44] in a study where liposomes and monolayers made
of soy bean phosphatidylcholine where used to evaluate drug–lipid interaction [44]. The authors
concluded that this membrane disordering effect could be related to myotoxicity. Manrique-Moreno
et al. also proposed that DCF induced a membrane fluidizing effect and hydration changes of the
lipid polar headgroups which could in turn have consequences at the membrane level, such as
changes in semipermeable properties, cell growth, and modulation of the activity of membrane
associated-enzymes [25].
DCF promotes calcein release in liposomes prepared with the main classes of lipids present in the
IMM, suggesting a membrane permeabilization either by a decrease in membrane microviscosity or
by induction of lateral phase separation with the advent of transient spaces at the interfacial regions
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that allow calcein leaking. The capacity of DCF to induce this effect must be related to the drug
location at the headgroup region of IMM membrane models perturbing the lipid packing of this
ordered membrane region. The high value of θ measured in IMM Lα phases before addition of DCF
confirms the high level of lipid order in the polar regions of this membrane model, probably due
to CL anionic groups interacting with Ca2+ divalent cations. It is at this level that DCF disordering
effects are more evident, also possibly owing to its negatively charged carboxylate group impairing
Ca2+ coordination, which may create a repulsive effect between the phospholipid headgroups.
The membrane permeabilization induced by DCF observed in our study can be further related to the
MPT effect at the mitochondrial membrane reported for this drug [18,19,32,33]. As observed for calcein
release studies, the increase in mitochondrial permeability may result from pore formation through
which ions can diffuse. The dissipation of the proton gradient across a permeable IMM can then result
in membrane depolarization and in impairment of ATP synthesis [18,19,32,33]. Ultimately, these effects
will lead to damaging of GI intercellular junctions and GI toxicity (as schematically represented in
Figure 1B) [6,11].
Furthermore, DCF preferential location at the headgroup region of the HII phases of the
IMM model is a synonym of a drug appetence for the contact points of mitochondria membranes.
At these sites, the insertion of DCF carboxylate group may also create a repulsive effect, inducing
a positive lateral pressure and disordering effect (also confirmed by the decrease of θ values with
DCF concentration). By inducing a positive lateral pressure, DCF can work as a bilayer stabilizer [73]
reducing the high negative curvature regions where the contact points between IMM and OMM occur.
This interference with membrane dynamics at the contact points of mitochondrial membranes has been
described for other compounds that act as bilayer stabilizers or HII phase promoters, and has been
pointed out as a cause of impairing H+-ATPase activity [74]. Moreover, the disturbance of membrane
lipid dynamics at mitochondria membrane contact points can be also related to DCF’s mitochondrial
toxicity by MPT-associated processes. This mitochondrial toxicity is very likely the pathway involved
in DCF-induced apoptosis, and the cumulative damage to mitochondrial function seems a plausible
putative mechanism to explain DCF hepatic, renal and cardiovascular deleterious effects that cannot
be explained by the COX inhibition mechanism [6,21–30].
Other studies reported the drug-interaction effects on membrane lipid organization, using
models mimicking the mitochondrial membrane and/or the native mitochondrial membrane, with
different drugs, namely piroxicam, nimesulide, menadione, and p-trifluoromethoxyphenylhydrazone
(FCCP) [57–60]. Generally, all the tested drugs interacted with the lipid membrane systems,
altering their structure and dynamics with several consequences: increase of membrane permeability,
a lipid disordering effect, changes in lipid phase transitions, and membrane fusion effects [57–60].
These observed biophysical effects also suggested a change in the curvature and elastic properties of
the membrane models and were coherent with the drugs’ mitochondrial toxic effects [57–60].
In summary, the DCF interactions with GI phospholipid model systems and IMM models
demonstrated in this work provide a novel molecular and biophysical perspective to explain the
reported topical harmful actions of DCF that could not be solely explained as resultant from COX
inhibition. Although several interesting and important studies have used animal and cellular models
to understand GI and mitochondrial toxicity of DCF [2,5,18,19,36,37,48,56,75], the use of lipid models
avoids the complexity of biological systems while providing a basis for evaluating the structural and
biophysical changes on lipid bilayers that are relevant for the functionality of native membranes.
Our work was carefully planned regarding the lipid systems used, as well as the conditions of study,
to provide a pertinent model for the lipid environment encountered by the drug in the biological milieu.
The concentrations of DCF studied (40 µM and the range 0–80 µM) were also chosen to be relevant in
a context of chronic use and toxicity level, while not excessively surpassing the drug plasmatic levels
(1.8–24.2 µM); this took into consideration the fact that NSAIDs reach particularly high concentrations
in tissues in which they cause effects and side effects and that we cannot take systemic concentrations as
surrogates for GI and mitochondrial concentrations [18,76]. Additionally, sub-cytotoxic concentrations
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of DCF (<100 µM) were described as able to cause mitochondrial dysfunction [48], and thus we used
this as the upper reference for the concentration range studied.
Future research directions, to complement the current work, could involve the study of DCF
interactions with lipid membranes by molecular dynamics (MD) simulations. Indeed, adsorption of
small molecules on lipid membranes has been studied by MD simulations to predict the effect of the
adsorbed agent in lipid membrane curvature [77]. Therefore, MD simulations could be applied to
study the effects of DCF in local membrane curvature, as this would be helpful to corroborate its effect
at the contact points of mitochondrial membranes. Furthermore, MD simulations might be very useful
for probing the molecular mechanism of membrane permeation processes [78] which is also relevant to
understand DCF interaction with GI lipid lining. Besides MD simulation studies, other experimental
approaches that could add relevant information to this work are time-resolved fluorescence anisotropy
for studying the restricted rotational diffusion of probes in membrane model systems. These studies
would allow evaluating DCF’s effect on the membrane microviscosity at Lβ’ phases as the surrounding
ordered media usually imposes certain restrictions on the orientations of the probe. Assays involving
the SAXS and WAXS studies of DCF and other NSAIDS in IMM models are also very relevant and
currently underway, and future assays with mitochondrial extracted membranes are also planned.
At this point, the study herein presented provides new elements for understanding previous
literature results regarding DCF toxicity and, from a molecular point of view, the additional knowledge
gained about DCF–membrane interaction may aid in the future design of safer NSAIDs for chronic
therapeutic purposes. Strategies to minimize a unique biochemical action of NSAIDs, such as by
coadministration of a phospholipid, esterification of NSAIDs (with or without the addition of hydrogen
sulfite or nitric oxide moieties), or use of selective COX2 inhibitors, have proven to be ineffective
in eliminating their toxicity. Strategies that affect NSAIDs’ topical actions, could be a more realistic
approach for reducing toxicity, namely by developing acid resistant nanoformulations that carry the
drug, protecting it from interacting with the lipid membranes at GI tract, and avoiding biophysical
impairment of mitochondrial membranes.
4. Materials and Methods
4.1. Materials
The lipids—DMPC, DPPC, DOPC, DOPE, and CL—were obtained from Avanti Polar Lipids
Inc. (INstruchemie, Delfzyl, The Netherlands) at a purity grade of >99% and were used without
further purification. Nonsteroidal anti-inflammatory drug, DCF, and the probes DPH and calcein were
purchased from Sigma-Aldrich Química, S.L. (Sintra, Portugal). All other chemicals were purchased
either from Sigma-Aldrich Química, S.L. or Cymit Quimica (Barcelona, Spain) and were of the highest
commercially available purity. Drug solutions were prepared either with Hepes buffer (pH 7.4) or
acetate buffer (pH 5.0).
4.2. Preparation and Labeling of Lipid Model Systems
Preparation of the lipid model systems was made by the lipid film hydration method followed by
extrusion previously reported [58–60]. Briefly, adequate portions of DMPC, DPPC, or ternary mixtures
of DOPC:DOPE:CL in a 1:1:1 molar ratio were dissolved in chloroform, and subsequently evaporated
to dryness in a rotary evaporator. The dry lipid films were hydrated with an adequate volume of buffer
(pH 5.0 for DPPC and DMPC, and pH 7.4 in the case of the ternary mixture to which a small volume of
CaCl2 to reach a 1:1 molar ratio of Ca2+:CL was also added) to achieve a final lipid concentration up
to 1500 µM, and vortexed 20 min. The lipid film hydration was performed at a temperature above
the Tm of the lipid or of the lipid mixture (37 ◦C for DMPC and ternary mixture and 55 ◦C for DPPC).
Lipid suspensions were then submitted to several freeze–thaw cycles and extruded through 100 nm
nucleopore polycarbonate filters (Millipore SAS, Molsheim, France) to produce LUVs.
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To obtain labeled lipid model systems, methanolic stock solutions of fluorescent probes were
added to the chloroform solutions of lipids in an amount such that the lipid:probe molar ratio is always
greater than 300:1, to prevent structural changes of the membrane model system. After addition
of the probe, lipid model systems were prepared by the lipid film hydration method followed by
extrusion described above. Increasing concentrations of DCF were added to LUVs (final concentration
of 1500 µM) labeled with TMA-DPH or DPH probes to obtain final drug concentration of 0–80 µM.
After mild shaking, the labeled LUVs suspensions were protected from light and incubated for 2 h
prior to measurements.
For calcein leakage studies, membrane model systems were prepared by the same lipid film
hydration method followed by extrusion where calcein (30 mM) was added in the buffer during the
hydration step. After the extrusion process, a molecular exclusion chromatography was performed to
exclude the excess of free probe from LUVs. Increasing concentrations of DCF were added to LUV
suspensions (final concentration of 1500 µM) containing calcein to obtain final drug concentration of
0–80 µM.
4.3. Derivative Spectrophotometry Studies
Kd of DCF was determined in LUVs of DMPC at pH 5.0. A series of samples containing increasing
concentrations of LUVs (0–1 mM) and a fixed concentration of DCF (40 µM) was prepared. A set of
reference samples was prepared identically but without the drug. The samples and references were
vortexed, mixed, and incubated at 37 ◦C.
The absorption spectra of samples and references were plotted in the 250–500 nm range, on a
Lambda 45 UV-Vis spectrophotometer (Perkin-Elmer, Villepinte, France) equipped with a thermostated
cell holder at 37.0 ± 0.1 ◦C. Derivative spectra were made from absorption spectra after subtracting
the absorption of the references and using an Excel®-based routine previously published [79].
Third-derivative spectra were determined to eliminate the spectral interferences due to light scattered
by the lipid suspensions and to improve the resolution of spectral bands. By representing the λmax
or λmin values of the third-derivative spectra as a function of the concentration of LUVs ([DMPC]),
a non-linear regression was obtained from which it was possible to determine Kd:
d3AbsT
dλ3
=
d3Absa
dλ3
+
(
d3Absl
dλ3
− d3Absa
dλ3
)
Kd[DMPC]Vl
1 + Kd[DMPC]Vl
(1)
In the fitting expression, AbsT, Absa, and Absl stand for total absorbance of the drug (in lipid and
aqueous media), absorbance of the drug in the aqueous media, and absorbance of the drug in the lipid
media, respectively. The LUV concentration, [DMPC] expressed in mol·L−1, is multiplied by the lipid
molar volume in L·mol−1 (Vl) to obtain a dimensionless value of Kd that can be compared with others
values described in the literature for other systems [50].
4.4. Fluorescence Quenching Studies
The fluorescence excitation and emission spectra of LUVs of DMPC or DOPC:DOPE:CL
(1:1:1) labeled with TMA-DPH and DPH probes were acquired using a Perkin-Elmer LS-50B
spectrofluorimeter using quartz cells of 10 mm optical path thermostated at 10.0, 30.0, 37.0,
and 45.0 ± 0.1 ◦C (for DMPC) or 25.0 and 70.0 ± 0.1 ◦C for ternary lipid mixture. In the case of
DMPC systems, temperatures were selected to evaluate the type of quenching mechanism established
between the probe and the drug, and to evaluate the drug location at two lipid phases: Lβ’ or gel phase
present at temperatures below Tm of DMPC, i.e., <23 ◦C, and Lα or fluid phase for the temperatures
above Tm of DMPC, i.e., >23 ◦C. These phases were studied for representing the disordered and
ordered regions that might be found in the GI phospholipid lining. In the case of the ternary lipid
model, temperatures were chosen to evaluate drug location at the lipid lamellar and non-lamellar
phases that can be found in IMM: Lα (at 25.0 ◦C) and HII (at 70.0 ◦C) [58–60].
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The excitation wavelength was defined to 360 nm and emission wavelength was set to 427 nm
with excitation and emission slits of 5 nm and a scan rate of 400 nm min−1. Fluorescence values were
corrected for light scattering contributions by subtracting the intensities from unlabeled samples at
the same conditions; such contributions were always negligible (less than 0.5%). All fluorescence
intensity data were corrected from absorption and inner filter effects [55]. Fluorescence lifetime
measurements were made with a Fluorolog Tau-3 Lifetime system (HORIBA Scientific, Piscataway,
NJ, USA). Modulation frequencies were acquired between 2 and 110 MHz. Integration time was
8 s. Manual slits used were 0.5 mm, slits for excitation and emission monochromator were 7.000 All
measurements were made using Ludox as a reference standard (τ = 0.00 ns).
The extent of fluorescence quenching induced by the quencher (DCF) in both probes (TMA-DPH
and DPH) was evaluated by Stern–Volmer constants (Ksv) obtained by the Stern–Volmer linear plots:
I0
I
or
τ0
τ
= 1 + Ksv[DCF]m (2)
where (I, τ) and (I0, τ0) are, respectively, the steady-state fluorescence emission and lifetime of the probe
in the presence or in the absence of the drug. Since only drug molecules distributed in the membrane
can quench the probes inserted in LUVs’ bilayers, membrane concentrations of the drug within the
membrane ([DCF]m) were used instead of total concentration of the drug added to the labeled systems
(0–80 µM). DCF membrane concentrations were calculated from total drug concentrations added using
the following equation [55,60]:
[DCF]m =
Kd[DCF]T
KdVm + (1 −Vm) (3)
where Kd is the distribution coefficient of DCF in the lipid system (calculated as described in Section 4.1)
and Vm is the membrane volume fraction [55,60].
The efficacy of DCF to quench the fluorescence of each probe was evaluated by the bimolecular
constant, Kq [50,55]:
Kq =
Ksv
τ0
(4)
Kq is independent of intrinsic microenvironment changes sensed by each probe, which are
reflected in the different values of τ0 (i.e., lifetime of the excited state characteristic of each probe [50,55])
and was used to infer the relative location of DCF (quencher) in the lipid model system.
4.5. Fluorescence Anisotropy Studies
Steady-state anisotropy of TMA-DPH and DPH probes included in DOPC:DOPE:CL (1:1:1)
systems in the presence of DCF (0–80 µM) was measured in a LS-50B spectrofluorimeter (Perkin-Elmer,
Villepinte, France), with quartz cell with an optical path of 10 mm, thermostated at 25.0 ± 0.1 ◦C or
70.0 ± 0.1 ◦C (for mimicking, respectively, Lα and HII phases of IMM) with automatic insertion of
vertical and horizontal polarizers. The probes were excited with vertical polarized light at a wavelength
of 360 nm and resultant fluorescence intensities were recorded at a wavelength of 427 nm, with the
emission polarizer oriented parallel (I‖) and perpendicular (I⊥) to the excitation polarizer allowing the
determination of steady-state anisotropy (rss):
rss =
I‖ − GI⊥
I‖ + 2GI⊥
(5)
The grating factor G is an instrumental preference of the emission optics for the horizontal
orientation to the vertical orientation. It can be measured by moving the excitation polarizer to the
horizontal orientation and comparing the intensities when the emission polarizer is vertically and
horizontally polarized, respectively.
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The rotational correlation time (θ) of the probes inserted in the ternary lipid model system
was calculated from the steady-state fluorescence anisotropy, rss, values using the following
equation [50,55,59]:
θ = τ
(
rss − r∞
r0 − rss
)
(6)
where τ are the measured lifetime values of each probe during the excited state and r0 is the
fundamental anisotropy (considered to be 0.362) [80]. We can assume the limiting anisotropy as
r∞ ≈ 0 since the rotational motion of the probe is not significantly hindered at the membrane fluid
phase (condition assured by making the measurements at temperatures above the Tm of the lipid
system). θ gives indications about probe motion, and indirectly reports the microviscosity of the lipid
environment surrounding the probe and how is it affected by the increasing concentrations of the DCF
(0–80 µM).
4.6. Calcein Leakage Studies
LUVs of DOPC:DOPE:CL (1:1:1) entrapping calcein were prepared as described in Section 4.1 and
were incubated with DCF (0–80 µM) for 10 min at 25 ◦C. Membrane destabilization accompanied by
calcein release was monitored in a LS-50B spectrofluorimeter (Perkin-Elmer, Villepinte, France) by
an increase of the fluorescence emission intensity at 520 nm upon excitation at 490 nm. Total (100%)
amount of calcein was determined after disrupting the lipid model systems upon addition of Triton
X-100. The results of the leakage experiments are presented as the calcein release (%), calculated
according to [58,60]:
Calcein release (%) =
100(Ix − Ic)
IT
(7)
where Ix is the fluorescence intensity with x DCF concentration, Ic is the control fluorescence (i.e.,
fluorescence of the lipid system in the absence of DCF), and IT is the maximum fluorescence value
reached upon lysis of the membrane systems.
4.7. Differential Scanning Calorimetry Studies
DSC measurements were performed using a microcalorimetry system (MicroCal VP-DSC, Malvern
Panalytical, Paralab, Lisbon, Portugal) as described elsewhere [23,81]. LUVs of DMPC (≈1 mg mL−1
resulting in a final lipid concentration of 1500 µM) with or without DCF (40 µM) and the buffer
(pH 5.0) used as reference were degassed before measurement and then were transferred to the
DSC sample holder. During the measurements, the samples were kept under nitrogen overpressure.
The scan rate employed was 1 ◦C min−1 in the temperature range between 15 and 35 ◦C after an
initial isothermal period of 15 min. The obtained data were analyzed using MicroCal Origin software.
After the calorimetric scans, aliquots of the scanned samples were used to determine the amount of
phospholipid by phosphorus assay [82].
4.8. Dynamic Light Scattering Studies
The main phase transition temperature and the cooperativity of LUVs of DMPC (1500 µM)
with or without DCF (40 µM) at pH 5.0 was determined by DLS, as already described in previously
reported studies [29,83]. The experiments were performed in a Zetasizer Nano ZS (Malvern Panalytical,
Paralab, Lisbon, Portugal) containing a controlled temperature cell holder. The samples were heated
from 10 to 40 ◦C with intervals of 1 ◦C with an equilibration period of 2 min. At each temperature,
3 runs of 2 min were made. The results were collected as average count rate versus temperature (T in
◦C) and the data were fitted using the following equation [29,83]:
Count rate = b1 + m1T +
b2 − b1 + m2T −m1T
1+ 10B(1/T−1/Tm)
(8)
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where m1 and m2 are the slopes of the linear fits to the data before and after the phase transition
region, respectively, and p1 and p2 are the corresponding y intercepts. From the fitted equation, Tm
and cooperativity (B) of the phase transition were obtained.
4.9. Syncrotron Small- and Wide-Angle X-ray Scattering Studies
For the X-ray scattering experiments, samples consisted of lipid dispersions of DPPC which had
not been extruded and was prepared as described in previous works [23,26,29,83]. Dispersions of
DPPC prepared in buffer of pH 5.0 in the absence or presence of DCF (40 µM) were transferred into
X-ray transparent glass capillaries with 1.5 mm diameter (Hilgenberg, Malsfeld, Germany), which were
sealed using a flame and stored at 4 ◦C until measurement. SAXS and WAXS scattering measurements
were recorded at the Austrian SAXS/WAXS beamline at the synchrotron light source ELETTRA (Trieste,
Italy) employing a monochromatic synchrotron radiation with wavelength of 1.54 Å and X-ray energy
of 8 keV. WAXS and SAXS patterns were recorded using a Pilatus 100K 2D and Pilatus 1M detector
system, respectively, with a pixel size of 172 µm at positions that covered the typical diffraction spacing
range (s = 2 sin θ/λ, where λ is the wavelength and 2θ is the scattering angle) of interest. The diffraction
spacings were calibrated using the lamellar peaks of silver behenate (SAXS) and p-bromo benzoic
acid (WAXS) as standards. Measurements were performed at temperatures between 20 and 50 ◦C
thermostated with a water bath (stability ±0.1 ◦C, Unistat CC, Huber, Offenburg, Germany) to obtain
the diffraction patterns typical of DPPC lipid phases (Lβ’, Pβ’, and Lα) and evaluate the effect of DCF
in such phases. After each temperature step, the sample was equilibrated for 5 min before the SAXS
and WAXS diffraction patterns were recorded for 30 s every minute. A shutter mounted before the
sample was kept closed when no data were acquired to minimize the X-ray exposure to the sample.
The integration of the scattered intensity and the primary data reduction was performed using the
program Fit2D. After the raw data had been corrected for detector efficiency, and the background
scattering both from water and the sample cell had been subtracted, all Bragg peaks were fitted
by Lorentzian distributions using Microcal Origin software. In each respective phase regime, only
the strongest reflections were considered. Each final diffraction pattern is presented as normalized
scattering intensity in arbitrary units versus the reciprocal spacing (s). fwhm were determined and
used to calculate the correlation length between the lipid bilayers (ξ = 2pi/fwhm). The repeat distances,
d (d = 1/s) were calculated from the peak positions of the diffraction patterns and given as an average
value of all the repeat distances measured.
From the WAXS patterns, it was possible to calculate the cross-sectional area of a single aliphatic
chain (A0). In the Lβ’ phase of the pure DPPC system, the unit cell is known to be orthorhombic and
this unit cell contains two aliphatic chains. The two parameters a and b of the orthorhombic cell are
calculated using the following equations:
a = 2d20 (9)
b = d11/
√(
1− (d11/2d20)2
)
(10)
in which d11 and d20 are the two distances determined by the peak positions on the X-ray pattern.
The sharp peak is attributed to d20 and the large peak to d11. In the samples where a symmetric peak
indicates that the chains are packed in a hexagonal lattice, the unit cell parameter a can be calculated by:
a = d202/
√
3 (11)
In this case of a hexagonal unit cell, the surface of the cell (a × d10) is directly the cross-section
area of one aliphatic chain.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/11/
3411/s1.
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Abbreviations
A0 Cross-sectional area of a single aliphatic chain
Absa Absorbance of the drug in the aqueous media
AbsT Total absorbance of the drug
Absl Absorbance of the drug in the lipid media
ATP Adenosine triphosphate
B Cooperativity of the main phase transition
CL Cardiolipin
ξ Correlation length
COX Cyclooxygenase
d Long or short spacing
DCF Diclofenac or sodium 2-[2-(2,6-dichloroaniline)phenyl]acetate
DLS Dynamic Light Scattering
DMPC 1,2-dimyristoyl-sn-glycero-3-phosphocholine
DOPC 1,2-dioleoyl-sn-glycero-3-phosphocholine
DOPE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine
DPH 1,6-diphenyl-1,3,5-hexatriene
DPPC 1,2-dipalmitoyl-sn-glycero-3-phosphocholine
DSC Differential Scanning Calorimetry
EPC Egg phosphatidylcholine
fwhm full width of the peaks at one-half of their intensity
GI Gastrointestinal
HII Inverted hexagonal phase
Ic Control fluorescence
IMM Inner mitochondrial membrane
IT Maximum fluorescence value
Ix Fluorescence intensity at a given drug concentration
Kd Distribution coefficient
Kq Bimolecular quenching rate constant
KSV Stern–Volmer constant
Lα Lamellar fluid phase
Lβ’ Lamellar gel phase (tilted chains)
Lβ Lamellar gel phase (untilted chains)
LUVs Large Unilamelar Vesicles
MPT Mitochondrial permeability transition pore
NSAID Non-steroidal anti-inflammatory drug
OMM Outer mitochondrial membrane
Pβ’ Ripple phase
PC Phosphatidylcholine
SAXS Small angle X-ray scattering
θ Rotational correlation time
rss Steady-state fluorescence anisotropy
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r0 Fundamental anisotropy
τ0 Lifetime of the excited state
Tm Main phase transition temperature
TMA-DPH N,N,N-Trimethyl-4-(6-phenyl-1,3,5-hexatrien-1-yl)phenylammonium p-toluenesulfonate
Tp Pre-transition temperature
TRP Transient receptor potential
Vm Membrane volume fraction
Vl Lipid molar volume
WAXS Wide Angle X-ray Scattering
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